Musculoskeletal

Rheumatoid arthritis: biologic therapy and monitoring

Clinical Overview and When to Suspect Biologic-Eligible RA

— Patient already carries an RA diagnosis (2010 ACR/EULAR criteria ≥6/10: joint count, serology, acute-phase reactants, symptom duration ≥6 wk)

— Moderate-to-high disease activity (DAS28 >3.2, CDAI >10, SDAI >11) despite ≥3 months of optimized methotrexate (MTX) at target dose 15–25 mg weekly, OR

— MTX intolerance/contraindication (hepatic disease, severe CKD, pregnancy planning, alcohol use disorder), OR

— Erosive disease on imaging, high-titer RF/anti-CCP, extra-articular features → "poor prognostic factors" that justify earlier biologic escalation

Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory polyarthritis driven by autoreactive T/B cells, synovial macrophages, and cytokine cascades (TNF-α, IL-6, IL-1, GM-CSF) producing pannus, cartilage loss, and bone erosion.

Prevalence ~0.5–1% US adults; female:male 2–3:1; peak onset 30–60 yr. Genetic risk: HLA-DRB1 "shared epitope," PTPN22; environmental: smoking, periodontitis, silica.

When to suspect biologic therapy is needed:

Goal of therapy per ACR 2021: treat-to-target remission (or low disease activity if remission unattainable) using sequential composite measures every 1–3 months.

Step 3 framing: you are usually the longitudinal manager—decisions revolve around when to add, switch, or stop a biologic; how to monitor safely; and how to coordinate with rheumatology, primary care, and specialty pharmacy.

Board pearl: ACR 2021 guideline endorses MTX monotherapy as the preferred first DMARD even in high-activity disease; biologics/JAKi are added (not substituted) when target not met. The old "triple therapy" (MTX + sulfasalazine + hydroxychloroquine) remains an option but is now conditional.

Key distinction: "Biologic" = injectable/infused monoclonal or fusion protein; JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are oral targeted synthetic DMARDs (tsDMARDs)—grouped with biologics for sequencing but with distinct safety signals (see chunk 11).

Presentation Patterns and Key History

— Prior/current infections: TB exposure, endemic mycoses (histoplasmosis, coccidioidomycosis), HBV/HCV/HIV, recurrent sinopulmonary or skin infections, diverticulitis (especially before IL-6 inhibitors—perforation risk)

— Malignancy history within 5 yr (lymphoma risk modifies TNFi choice; avoid in active malignancy)

— Demyelinating disease/MS or optic neuritis → contraindicates TNF inhibitors

— CHF NYHA III–IV → avoid TNFi (worsens HF)

— Pregnancy plans in patient or partner—affects MTX, leflunomide, JAKi choices

— Vaccination status: shingles, pneumococcal, influenza, COVID, HBV; live vaccines must be given BEFORE biologic initiation (zoster RZV is non-live and safe)

— Tobacco, alcohol, occupational exposures

Classic RA presentation: insidious, symmetric polyarthritis of small joints—MCPs, PIPs, wrists, MTPs—with morning stiffness >60 minutes that improves with activity. Often spares DIPs (vs. OA, psoriatic arthritis).

Constitutional: low-grade fever, fatigue, weight loss, depression. Extra-articular: rheumatoid nodules, scleritis/episcleritis, sicca, interstitial lung disease (RA-ILD, UIP pattern most common), pericarditis, Felty syndrome (RA + splenomegaly + neutropenia), secondary Sjögren, vasculitis, AA amyloidosis (rare with modern Rx).

History to obtain before starting a biologic (Step 3 favorite):

Functional history: HAQ-DI, ability to work, ADLs, grip strength, assistive device use. Patient-reported outcomes drive shared decision-making about route (SC vs. IV) and frequency.

Step 3 management: Before any biologic, document negative TB screen (IGRA preferred over PPD in BCG-vaccinated), HBsAg + anti-HBc + anti-HBs, HCV Ab, HIV, CBC, CMP, and update age-appropriate cancer screening. Latent TB → treat ≥1 month of isoniazid before starting biologic; complete full 9-month course concurrently.

Board pearl: A patient on a TNFi who develops new paresthesias and optic symptoms—stop the drug and obtain MRI brain/spine; demyelination is an absolute contraindication to continued TNFi.

Physical Exam Findings and Disease Activity Assessment

— Inspect for synovitis: boggy, warm, tender swelling at MCPs/PIPs/wrists/MTPs; "squeeze test" across MCPs and MTPs reproduces tenderness early in disease

— Late deformities: ulnar deviation at MCPs, swan-neck (PIP hyperextension + DIP flexion), boutonnière (PIP flexion + DIP hyperextension), Z-thumb, hammer/cock-up toes, hindfoot valgus, C1–C2 atlantoaxial subluxation (neurologic red flag before intubation/surgery)

— Rheumatoid nodules over extensor surfaces (olecranon, Achilles)—may paradoxically worsen on MTX

— DAS28-CRP or DAS28-ESR: 28 joints + global + CRP/ESR; remission <2.6, low ≤3.2, moderate >3.2–5.1, high >5.1

— CDAI (no labs needed): remission ≤2.8, low ≤10, moderate ≤22, high >22—useful in clinic when labs unavailable

— SDAI = CDAI + CRP

— RAPID3: patient-reported, 3 items, useful in primary care follow-up

— Resting tachycardia or new edema → screen for TNFi-induced HF exacerbation

— Hypotension during infliximab/rituximab infusion → infusion reaction; pretreat with acetaminophen, diphenhydramine, ±steroid

Joint exam is the cornerstone of monitoring biologic response.

Composite disease-activity scores you must know and trend:

Extra-articular exam: lung crackles (ILD), eye exam (scleritis), skin (vasculitic ulcers, livedo), neuro (mononeuritis multiplex, cervical myelopathy signs—Hoffmann, Lhermitte).

Functional/hemodynamic considerations on biologics:

CCS pearl: On a CCS case, after starting or escalating a biologic, advance the simulated clock 4–12 weeks and re-order CDAI/DAS28 and CRP—do not wait 6 months to reassess. Treat-to-target requires a measurement every 1–3 months until target achieved, then every 6 months.

Board pearl: Any RA patient needing intubation, cervical manipulation, or general anesthesia gets flexion-extension cervical spine films to evaluate atlantoaxial instability.

Diagnostic Workup — Initial Labs, Serology, and Imaging

— Rheumatoid factor (RF): sensitivity ~70%, specificity ~85%; also seen in HCV, Sjögren, endocarditis, cryoglobulinemia

— Anti-cyclic citrullinated peptide (anti-CCP/ACPA): sensitivity ~70%, specificity ~95%; predicts erosive disease and extra-articular manifestations, especially RA-ILD

— High-titer RF + anti-CCP → poor prognostic factor → favor earlier biologic

— IGRA (QuantiFERON or T-SPOT) for latent TB

— HBsAg, anti-HBc total, anti-HBs—anti-HBc+/HBsAg− carries reactivation risk, especially with rituximab → prophylactic entecavir

— HCV Ab, HIV Ag/Ab

— Hand and foot radiographs at baseline: periarticular osteopenia, joint-space narrowing, marginal erosions (especially 2nd–3rd MCPs, ulnar styloid, 5th MTP)

— MSK ultrasound with power Doppler detects subclinical synovitis—drives "treat-to-target" beyond exam

— MRI for early erosions/bone marrow edema when X-ray is normal but clinical suspicion is high

— HRCT chest if cough, dyspnea, crackles, or high anti-CCP → screen RA-ILD before TNFi (some TNFi may worsen ILD)

Diagnosis is typically already established before biologic decisions, but Step 3 stems often ask you to confirm or re-evaluate.

Baseline serology (high yield):

Acute-phase reactants: ESR, CRP—track activity and response; CRP normalizes faster than ESR

CBC: anemia of chronic disease, thrombocytosis (active inflammation), neutropenia (Felty)

CMP: baseline LFTs, creatinine—needed for MTX/leflunomide dosing and tofacitinib lipid monitoring

UA: proteinuria → consider amyloid or drug nephrotoxicity

Pre-biologic infectious panel (mandatory):

Imaging:

Board pearl: Anti-CCP positivity in an undifferentiated arthritis predicts progression to RA and is the single best test to justify early aggressive (biologic-eligible) therapy.

Key distinction: RF and anti-CCP are not monitored serially to gauge treatment response—use CRP, ESR, and composite scores instead.

Diagnostic Workup — Advanced and Confirmatory Studies

— Detects synovial hypertrophy, effusion, erosions, and active vascularity

— Used to confirm clinical remission (a patient may have CDAI remission but persistent Doppler signal → "subclinical synovitis" predicting flare and erosion)

— Helpful for joint injection guidance during flares

— Gold-standard sensitivity for bone marrow edema (osteitis), the earliest erosion precursor

— Useful in seronegative cases and to differentiate RA from inflammatory OA or psoriatic arthritis

MSK ultrasound (US) with power Doppler:

MRI hands/wrists:

HRCT chest: Suspect RA-ILD when bibasilar crackles, restrictive PFTs, or unexplained dyspnea; UIP pattern carries worst prognosis. Consider rituximab or abatacept preferentially over TNFi in RA-ILD (TNFi may worsen ILD per registry data).

PFTs with DLCO: baseline in smokers, high anti-CCP, or any pulmonary symptoms before initiating biologic; repeat for new dyspnea.

Echocardiogram: baseline if any CHF history before TNFi; RA itself increases cardiovascular mortality ~1.5×.

Cervical spine flexion/extension films or MRI: before elective surgery or in patients with neck pain, paresthesias, or gait change—rule out atlantoaxial subluxation (anterior atlantodental interval >3 mm) or basilar invagination.

Bone density (DXA): at baseline and periodically; chronic inflammation + likely glucocorticoid exposure → high osteoporosis risk.

Lipid panel & HbA1c: baseline and 4–8 wk after starting tocilizumab or JAK inhibitor (both raise LDL/triglycerides).

Pregnancy test (β-hCG): before MTX, leflunomide, JAKi, or any new DMARD in reproductive-age patients.

Synovial fluid analysis: WBC 2,000–50,000 with PMN predominance, sterile, no crystals—used mainly to exclude septic arthritis or crystal disease in a single hot joint on a biologic (immunosuppression raises septic arthritis risk dramatically).

Step 3 management: A patient on a biologic with a single acutely swollen, red, hot joint—do not assume RA flare. Arthrocentesis first to exclude septic joint; hold biologic; empiric vancomycin pending Gram stain/culture.

Risk Stratification and Treatment Sequencing Logic

1. Methotrexate monotherapy (oral or SC), titrate to 15–25 mg/wk over 4–6 wk with folic acid 1 mg/day; bridge with short-course low-dose prednisone (≤3 months, taper aggressively)

2. If target not met at 3 months: optimize MTX dose/route (switch oral → SC for better bioavailability), then add either a biologic (preferred: TNFi) or a JAK inhibitor

3. If first biologic fails: switch within class (TNFi→TNFi) or, if primary non-response or two TNFi failures, switch to different mechanism (abatacept, rituximab, tocilizumab/sarilumab, or JAKi)

— High disease activity, functional limitation, extra-articular disease, RF+/anti-CCP+, early erosions

— CHF (NYHA III–IV) → avoid TNFi; use abatacept or rituximab

— Demyelinating disease → avoid TNFi

— Hepatitis B (anti-HBc+) → avoid rituximab if possible; if needed, give entecavir prophylaxis

— Hepatitis C → TNFi (especially etanercept) generally safe; coordinate with hepatology

— Recent solid tumor → rituximab preferred (does not increase tumor recurrence per registry data)

— Lymphoma → avoid TNFi; rituximab appropriate

— RA-ILD → rituximab or abatacept preferred over TNFi

— Recurrent infections/diverticulitis → avoid tocilizumab (perforation), JAKi (zoster)

— High CV risk, age ≥65, smokers → avoid JAK inhibitors (ORAL Surveillance trial: ↑MACE, malignancy, VTE vs. TNFi)

ACR 2021 sequencing for established RA:

Poor prognostic factors that justify earlier biologic add-on:

Choice of biologic by comorbidity (Step 3 favorite matrix):

Board pearl: Post-2021 FDA boxed warning: in patients ≥50 with ≥1 CV risk factor, TNF inhibitors are preferred over JAK inhibitors based on the ORAL Surveillance trial showing increased MACE, malignancy, VTE, and all-cause mortality with tofacitinib.

Step 3 management: Document a target (remission vs. low activity), reassess every 1–3 months using CDAI/DAS28, and escalate or switch if target not met—do not allow indefinite "moderate activity."

Pharmacotherapy — Biologic and Targeted Drug Classes in Depth

— Etanercept (SC weekly): soluble TNF receptor fusion protein

— Adalimumab (SC q2wk), golimumab (SC q4wk), certolizumab pegol (SC q2–4wk; PEGylated Fab, preferred in pregnancy—minimal placental transfer)

— Infliximab (IV q8wk after loading): chimeric mAb; risk of antidrug antibodies → combine with MTX

— AEs: infection, reactivation TB/HBV, demyelination, drug-induced lupus, injection/infusion reactions, paradoxical psoriasis, possible HF worsening

— Tocilizumab (IV monthly or SC weekly), sarilumab (SC q2wk)

— AEs: ↑LFTs, neutropenia, dyslipidemia, GI perforation (avoid in diverticulitis), CRP becomes unreliable as activity marker—use CDAI

— Abatacept (CTLA-4-Ig; IV monthly or SC weekly): favorable safety in ILD, lower infection risk, slower onset

— Rituximab (anti-CD20; two 1 g IV infusions 2 wk apart, repeat q6mo): preferred in lymphoma history, RA-ILD, RF+/anti-CCP+; check HBV serology (reactivation risk—give entecavir if anti-HBc+); monitor IgG (hypogammaglobulinemia with repeated cycles)

— Tofacitinib, baricitinib, upadacitinib

— AEs (boxed): MACE, malignancy (lymphoma, NMSC), VTE/PE, serious infection, herpes zoster (give RZV before starting), ↑lipids, ↑CPK, cytopenias

— Avoid in age ≥65, smokers, CV/VTE risk unless TNFi failed/contraindicated

— Biologic + MTX > biologic monotherapy (reduces antidrug antibodies, esp. infliximab/adalimumab)

— Never combine two biologics or biologic + JAKi → excess infection without efficacy gain

TNF-α inhibitors (first-line biologic class):

IL-6 receptor inhibitors:

T-cell costimulation blocker:

B-cell depleter:

JAK inhibitors (oral tsDMARDs):

IL-1 (anakinra) and anti-GM-CSF are rarely used in RA; anakinra more common in adult-onset Still disease.

Combination rules:

Board pearl: Tocilizumab normalizes CRP regardless of disease activity—use clinical/CDAI assessment, not CRP, to judge response.

Step 3 management: Hold biologic for active serious infection; resume only after clinical resolution and completion of antibiotic course.

Procedures, Vaccination, and Perioperative Management

— Labs: CBC, CMP, HBV panel, HCV Ab, HIV, IGRA, β-hCG, lipids

— Imaging: CXR, hand/foot films, HRCT if respiratory symptoms

— Cancer screening up to date

— Vaccinations completed ideally ≥2–4 weeks before starting (especially live vaccines):

◦ Inactivated/recommended on biologic: influenza (annual), pneumococcal (PCV20 or PCV15+PPSV23), recombinant zoster (RZV) for age ≥18 on immunosuppression, HBV, HPV, COVID, Tdap

◦ Live vaccines contraindicated on biologics: MMR, varicella, live zoster (Zostavax—obsolete), yellow fever, intranasal flu, oral typhoid, BCG

— Hold biologic through one full dosing interval; schedule surgery at the end of that interval (e.g., adalimumab q2wk → surgery in week 3; rituximab → surgery in month 7 of 6-month cycle)

— Hold JAK inhibitors 3 days before surgery

— Continue MTX, hydroxychloroquine, sulfasalazine, leflunomide through surgery

— Continue prednisone at current dose; do not stress-dose unless adrenal insufficiency suspected

— Resume biologic ~14 days postop if wound healed, no infection, sutures out

— Infliximab/rituximab/tocilizumab IV require infusion center; pretreat with acetaminophen ± diphenhydramine; methylprednisolone before rituximab

— Manage infusion reactions: slow rate, antihistamines, steroids; anaphylaxis → epinephrine, stop

Pre-initiation checklist (the "biologic safety bundle"):

Perioperative biologic management (ACR/AAHKS 2022 guidance for elective hip/knee arthroplasty):

Infusion logistics:

Intra-articular glucocorticoid injection (triamcinolone 40 mg) is appropriate for monoarticular flare while overall regimen is otherwise effective—do not abandon biologic for a single joint.

CCS pearl: On a CCS case of elective TKA in an RA patient on adalimumab and MTX: continue MTX, schedule surgery at end of adalimumab dosing interval, give standard surgical antibiotic prophylaxis, resume adalimumab ~2 weeks postop after wound check.

Board pearl: Always give recombinant zoster vaccine (RZV) to RA patients ≥18 on immunosuppression—it is non-live, safe, and especially important before JAK inhibitors.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline infection, malignancy, CV risk → TNF inhibitors preferred over JAK inhibitors per ORAL Surveillance

— Etanercept may have slightly lower serious infection rate than infliximab in older adults

— Beware polypharmacy: combine biologic + MTX cautiously; reduce MTX dose for sarcopenia and reduced GFR

— Increased risk of herpes zoster—give RZV before any biologic/JAKi

— Falls risk + osteoporosis: DXA, calcium/vitamin D, bisphosphonate if glucocorticoid ≥7.5 mg/day for ≥3 months

— Vaccinate aggressively: PCV20, RZV, annual influenza, COVID boosters

— MTX is renally cleared—avoid if eGFR <30, dose-reduce if 30–60

— Leflunomide: no dose adjustment for CKD but caution

— Biologics: generally no renal dose adjustment (large proteins cleared by reticuloendothelial system)—favorable in advanced CKD

— JAK inhibitors: dose-reduce tofacitinib (5 mg daily if eGFR <60), baricitinib (2 mg daily if eGFR 30–60; avoid <30)

— Dialysis patients: biologics generally acceptable; avoid MTX

— Avoid MTX and leflunomide in significant liver disease (Child-Pugh B/C, transaminases >2× ULN, active hepatitis)

— Hepatitis B: anti-HBc+ → entecavir or tenofovir prophylaxis during and ≥6–12 months after biologic (especially rituximab)

— Hepatitis C: treat with DAAs ideally before biologic; if active, TNFi (etanercept) considered relatively safe

— Tocilizumab/sarilumab and JAKi can ↑transaminases—hold if ALT >5× ULN

Elderly (≥65 yr):

Chronic kidney disease:

Hepatic impairment:

Frailty considerations: lower target intensity (low disease activity rather than remission) may be acceptable; emphasize function (HAQ-DI), avoid prolonged glucocorticoids.

Step 3 management: In an 80-year-old smoker with stable RA on tofacitinib who develops chest pain or a PE, discontinue JAK inhibitor permanently and transition to a TNF inhibitor (or non-TNF biologic) after event stabilization—the FDA boxed warning makes continuation indefensible.

Board pearl: Biologics have minimal renal/hepatic clearance—often the safest DMARDs in advanced CKD when MTX is contraindicated.

Special Populations — Pregnancy, Lactation, and Family Planning

— Methotrexate: abortifacient and teratogen—stop ≥3 months before conception (men and women); ensure contraception; continue folic acid

— Leflunomide: long half-life—cholestyramine washout (8 g TID × 11 days) and verify plasma levels <0.02 mg/L twice before conception

— JAK inhibitors: avoid in pregnancy and lactation (animal teratogenicity, insufficient human data)

— Cyclophosphamide, mycophenolate: contraindicated

— Hydroxychloroquine, sulfasalazine (with folic acid supplementation), azathioprine, low-dose prednisone (<20 mg)

— TNF inhibitors: generally continued through 2nd trimester; certolizumab pegol has minimal placental transfer (no Fc region) → preferred and may continue throughout pregnancy

— Etanercept and adalimumab often continued into 3rd trimester if needed, then held

— Infants exposed to TNFi in utero: delay live vaccines (rotavirus, BCG) until 6–12 months; inactivated vaccines on schedule

Pre-conception counseling is a Step 3 staple. RA often improves during pregnancy (~60%) and flares postpartum.

Teratogenic / contraindicated in pregnancy:

Acceptable during pregnancy:

Lactation: TNFi, certolizumab, hydroxychloroquine, sulfasalazine, prednisone, and rituximab considered compatible; avoid MTX, leflunomide, JAKi, tofacitinib.

Paternal exposure: MTX in men—stop ≥3 months before conception (older guidance; newer data suggest lower risk but conservative practice persists); TNFi acceptable in fathers.

Pediatric RA (JIA): different disease; etanercept, adalimumab, tocilizumab, abatacept FDA-approved; uveitis screening with slit-lamp every 3–12 months depending on subtype.

Postpartum flare: anticipate, plan reinitiation of biologic immediately postpartum if not breastfeeding-restricted.

Step 3 management: A woman with RA planning pregnancy on MTX + adalimumab: stop MTX 3 months pre-conception, switch or transition to certolizumab pegol, ensure folate 1 mg/day, update vaccines, and counsel that disease may improve in pregnancy but flare postpartum.

Board pearl: Certolizumab pegol is the biologic of choice in pregnancy due to lack of Fc-mediated placental transfer.

Complications and Adverse Outcomes of Biologic Therapy

— Bacterial (pneumonia, cellulitis, UTI), opportunistic (TB reactivation, histoplasmosis, listeria, PJP rare), viral (HBV reactivation, herpes zoster—highest with JAKi, then tocilizumab)

— CCS pearl: Any febrile RA patient on a biologic gets blood cultures, CXR, UA, and a low threshold for empiric antibiotics; hold the biologic until infection cleared.

— Baseline RA ↑lymphoma risk; TNFi adds modestly to non-melanoma skin cancer risk—annual dermatologic exam

— JAK inhibitors: ↑lymphoma and lung cancer per ORAL Surveillance (especially smokers ≥50)

— Rituximab is safest with prior cancer history

— JAKi: ↑MACE, VTE/PE (boxed warning); screen and counsel

— TNFi: avoid in NYHA III–IV HF

— All biologics: monitor BP, lipids, glucose (RA itself ↑CV mortality)

Infections (most common serious AE):

Malignancy:

Cardiovascular and thromboembolic:

Hematologic: neutropenia/thrombocytopenia with tocilizumab, rituximab, JAKi; hypogammaglobulinemia with repeated rituximab cycles (check IgG before each cycle)

Hepatotoxicity: ↑ALT/AST with tocilizumab, JAKi, MTX; hold if ALT >3–5× ULN

Dermatologic: injection site reactions, paradoxical psoriasis (TNFi), psoriasiform eruptions, eczema

Neurologic: demyelination (TNFi), PML (extremely rare with rituximab)

GI perforation: tocilizumab/sarilumab—avoid in diverticulitis history; warn about abdominal pain

Drug-induced lupus: TNFi—ANA/anti-dsDNA seroconversion common but clinical lupus rare; stop drug

Antidrug antibodies: especially infliximab and adalimumab → loss of efficacy; co-administer MTX to suppress immunogenicity

Vaccine-preventable diseases: influenza, pneumococcal pneumonia, zoster, COVID—keep vaccines current

Board pearl: New-onset severe abdominal pain in a patient on tocilizumab = consider diverticular perforation, even without fever or peritoneal signs (IL-6 blockade suppresses inflammatory response). Order CT abdomen/pelvis with contrast urgently.

When to Escalate Care — Inpatient, ICU, Consultation Triggers

— Failure to meet treatment target after 3 months on optimized DMARD/biologic

— New extra-articular manifestation (scleritis, ILD, vasculitis, mononeuritis multiplex)

— Cytopenia, transaminitis on therapy

— Suspected RA-ILD on imaging → also pulmonology

— Fever in a patient on biologic → sepsis workup; assume serious infection until proven otherwise

— Hot single joint → arthrocentesis to exclude septic arthritis (Staph aureus most common; risk ~10× general population)

— Acute dyspnea → r/o PE (JAKi risk), HF (TNFi worsening), PJP, drug-induced pneumonitis (MTX), RA-ILD acute exacerbation

— Acute abdomen on tocilizumab → CT for diverticular perforation

— Acute neurologic deficit/optic symptoms on TNFi → MRI for demyelination

— New chest pain, leg swelling on JAKi → ECG, troponin, D-dimer, CTA chest

— Sepsis, opportunistic infection, organ failure, suspected GI perforation, suspected septic joint, severe drug reaction (anaphylaxis, DRESS, SJS)

— Infectious disease for opportunistic infections, TB reactivation, HBV reactivation

— Pulmonology for ILD

— Cardiology for HF exacerbation or post-MI risk stratification

— Hematology/oncology for new lymphoma or cytopenia

— Ophthalmology for scleritis or uveitis

— Orthopedics for joint replacement planning

Outpatient rheumatology referral (urgent, <2 weeks):

Emergency department triage:

Hospital admission indications:

ICU triggers: septic shock, respiratory failure (PJP, ILD exacerbation), massive PE, GI perforation with peritonitis

Consultations to coordinate:

Step 3 management: In a hospitalized RA patient on a biologic with proven infection: hold biologic and MTX, continue hydroxychloroquine if needed, manage flare with low-dose prednisone if joints active, treat infection fully, then resume biologic after clinical resolution and antibiotic completion (typically 1–2 weeks after course ends).

CCS pearl: Document "hold biologic" as an explicit order on admission for any infectious presentation—failure to do so is a common CCS point loss.

Key Differentials — Other Inflammatory Arthritides

— Asymmetric oligoarthritis, DIP involvement, dactylitis ("sausage digit"), enthesitis, nail pitting/onycholysis, psoriasis (may be subtle—scalp, umbilicus, gluteal cleft)

— RF and anti-CCP usually negative; HLA-B27 ~25%

— Biologics overlap (TNFi, IL-17 [secukinumab, ixekizumab], IL-23 [guselkumab], JAKi)

— Inflammatory back pain (age <45, morning stiffness, improves with activity), sacroiliitis on MRI/X-ray, HLA-B27+

— Peripheral arthritis less common; uveitis, enthesitis

— TNFi and IL-17 inhibitors first-line biologics; rituximab and abatacept not effective

— Age >50, proximal shoulder/hip girdle stiffness, ESR >40, dramatic response to prednisone 15–20 mg/day; rarely needs biologics, though sarilumab now FDA-approved for refractory PMR

— Coexists with giant cell arteritis (treat with tocilizumab + steroids)

Psoriatic arthritis (PsA):

Ankylosing spondylitis / axial spondyloarthritis:

Reactive arthritis: post-GU (Chlamydia) or post-GI (Salmonella, Shigella, Yersinia, Campylobacter) infection; oligoarticular, lower extremity, conjunctivitis, urethritis, keratoderma blennorrhagicum.

Adult-onset Still disease (AOSD): quotidian high fevers, salmon-pink evanescent rash, arthritis, hyperferritinemia (>5× ULN), leukocytosis; treated with IL-1 (anakinra, canakinumab) or IL-6 (tocilizumab) blockade.

Juvenile idiopathic arthritis (JIA): pediatric; subtypes (oligoarticular, polyarticular RF+/–, systemic, enthesitis-related, psoriatic); biologics: etanercept, adalimumab, tocilizumab, abatacept, canakinumab.

Polymyalgia rheumatica (PMR):

Crystal arthropathies (gout, CPPD): mono/oligoarticular, crystals on aspiration; can mimic flares but require different therapy—do not escalate biologic.

Connective tissue diseases (SLE, mixed CTD): Jaccoud's arthropathy mimics RA but non-erosive; check ANA, anti-dsDNA, anti-Sm, complements.

Board pearl: A non-erosive deforming arthritis with positive ANA and low complements points to SLE/Jaccoud, not RA, despite hand deformities.

Key distinction: RA spares DIPs; OA and PsA prominently involve DIPs. Symmetric small-joint involvement + positive anti-CCP virtually clinches RA.

Key Differentials — Non-Rheumatologic Mimics

— Older, weight-bearing joints, DIP (Heberden) and PIP (Bouchard) nodes, first CMC, knees, hips

— Morning stiffness <30 min, worse with use

— Normal CRP/ESR; X-ray: osteophytes, joint-space narrowing, subchondral sclerosis (no erosions)

— Management: acetaminophen, topical NSAIDs, exercise; biologics not indicated

— Parvovirus B19 in adults: symmetric polyarthritis mimicking RA, self-limited weeks; check parvovirus IgM

— Hepatitis C: cryoglobulinemic arthritis; check HCV before assuming RA, especially with RF+ but anti-CCP−

— HIV, HBV, rubella, chikungunya, alphaviruses

— Post-COVID arthralgia

Osteoarthritis (OA):

Viral arthritis:

Lyme arthritis: late stage; large joints (knee), endemic exposure, Lyme serology; treat with doxycycline.

Endocrine: hypothyroidism (myalgia, carpal tunnel, joint stiffness); hyperparathyroidism; hemochromatosis (2nd/3rd MCP "iron fist," chondrocalcinosis, transferrin saturation >45%).

Infiltrative: amyloid arthropathy (dialysis patients, β2-microglobulin), sarcoid arthropathy (acute Löfgren: arthritis + erythema nodosum + hilar adenopathy).

Paraneoplastic: hypertrophic osteoarthropathy (clubbing, periostitis—classically lung cancer); palmar fasciitis; remitting seronegative symmetrical synovitis with pitting edema (RS3PE—older men, may herald malignancy).

Fibromyalgia: widespread pain without synovitis, tender points, fatigue, sleep disturbance; normal labs and imaging—do not prescribe biologics. Often coexists with RA and confounds activity scores.

Drug-induced arthralgia: aromatase inhibitors, statins, fluoroquinolones, immune checkpoint inhibitor arthritis (mimics RA; may require steroids/biologics).

Board pearl: Acute symmetric polyarthritis in a young woman after daycare exposure → parvovirus B19; serology and observation, not biologics.

Key distinction: Normal ESR/CRP with hand pain and no synovitis on exam = OA or fibromyalgia, not RA—do not start a biologic without objective inflammation.

Long-Term Plan, Secondary Prevention, and Comorbidity Management

— Once remission/low activity achieved and sustained ≥6 months, consider tapering (not abrupt stop): reduce glucocorticoids first → space biologic dosing → consider MTX dose reduction last

— Do not stop biologic completely if patient has erosive/seropositive disease—flare risk is high

— Aggressive lipid management—statin per ASCVD risk

— BP control, smoking cessation (also slows RA progression and improves drug response)

— Aspirin only for established ASCVD

— DXA at baseline and q2 years

— Calcium 1000–1200 mg/day, vitamin D 800–1000 IU/day

— Bisphosphonate if T-score ≤−2.5, fragility fracture, or prednisone ≥7.5 mg/day × ≥3 months (or FRAX-elevated)

— Annual influenza (inactivated), PCV20 (or PCV15 + PPSV23), RZV (≥18 yr on immunosuppression), HBV if susceptible, COVID-19 boosters per CDC, HPV if eligible

— Travel medicine consult before live vaccines (yellow fever, oral typhoid)—hold biologic per timing guidelines if essential

Treat-to-target maintenance:

Cardiovascular risk reduction (RA ≈ DM in CV risk per EULAR; multiply ASCVD score by 1.5):

Osteoporosis prevention:

Infection prevention:

Cancer screening: annual skin exam (NMSC risk), age-appropriate breast/colon/cervical/lung screening; emphasize for JAKi users.

Mental health: depression in 15–20% of RA patients—screen PHQ-2/PHQ-9 annually; treat to improve disease outcomes.

Dental/periodontal care: periodontitis worsens RA activity (P. gingivalis citrullination hypothesis); routine cleanings.

Lifestyle: Mediterranean diet, moderate aerobic + resistance exercise, weight management, omega-3 supplementation (modest benefit).

Step 3 management: At every RA visit, address the "RA Big 5" longitudinal items: disease activity score, CV risk, bone health, infection prophylaxis/vaccines, mental health screen. Forgetting any of these is a frequent missed-points item on CCS.

Board pearl: Treat RA as a CV-risk-equivalent—statin and BP optimization are as important as DMARD therapy for long-term mortality reduction.

Follow-Up, Monitoring Parameters, and Patient Counseling

— Active disease: every 1–3 months until target met

— Stable remission: every 3–6 months

— Coordinate primary care + rheumatology visits (shared care model)

— CBC, CMP (including LFTs) every 2–4 weeks initially, then every 3 months once stable

— Lipid panel 4–8 weeks after starting tocilizumab/sarilumab/JAKi, then annually

— Annual TB screening (IGRA) while on biologic if ongoing exposure risk

— Quantitative immunoglobulins before each rituximab cycle (hold if IgG <5–6 g/L with recurrent infections)

— HBV DNA periodically if anti-HBc+ on prophylaxis

— Hand/foot X-rays annually for the first 2–3 years to assess radiographic progression

— HRCT/PFTs if pulmonary symptoms develop

— Recognize and report signs of infection promptly (fever, dysuria, cough, cellulitis, severe abdominal pain)

— Hold next biologic dose for any active infection; resume after consultation

— SC injection technique, rotate sites, sharps disposal

— Refrigeration of medication; travel logistics

— Avoid live vaccines; ensure household members do not receive oral polio or get nasal flu mist (inactivated flu OK)

— Reproductive planning before initiating teratogenic agents

— Sun protection (↑NMSC risk)

— Smoking cessation, alcohol limits (<1 drink/day with MTX)

— Occupational therapy for joint protection, assistive devices, splints

— Physical therapy for ROM and strengthening, especially after flares

— Hand surgery referral for severe deformity, tendon rupture, carpal tunnel

Visit cadence:

Laboratory monitoring on biologics:

Imaging monitoring:

Disease activity monitoring: CDAI or DAS28 at every visit; document target attainment

Patient counseling checklist:

Rehabilitation:

Adherence and access: specialty pharmacy coordination, prior authorization, biosimilar substitution awareness (infliximab, adalimumab, etanercept, rituximab biosimilars now standard).

CCS pearl: On a CCS RA case, advance the clock and re-order CBC, CMP, and CDAI at 4 weeks, then 3 months—neglecting interval labs is a common scoring miss.

Ethical, Legal, and Patient Safety Considerations

— Document discussion of infection risk (including TB and HBV reactivation), malignancy (especially lymphoma, NMSC, and for JAKi: lung cancer, MACE, VTE), demyelination (TNFi), pregnancy/teratogenicity, infusion reactions, and cost/access

— FDA boxed warnings must be explicitly disclosed—particularly JAK inhibitor boxed warnings for MACE, VTE, malignancy, and mortality in ≥50-year-olds with CV risk; failing to document this conversation is a medicolegal vulnerability

— Route preference (oral JAKi vs. SC vs. IV), frequency, cost, lifestyle (travel, refrigeration), child-bearing plans

— Use plain-language risk communication: absolute risk increases, not just relative

— Hospital discharge in an RA patient: explicitly document whether biologic is held or resumed, with a clear date and the responsible provider (PCP vs. rheumatology). Lack of this handoff is a leading cause of missed doses and flares.

— Medication reconciliation: include specialty pharmacy contact, last dose date, next dose due date

— Inform PCP and surgeon when stopping/starting biologics perioperatively

Informed consent for biologics:

Shared decision-making:

Transitions of care (Step 3 favorite):

Vaccination safety: confirm live-vaccine avoidance; counsel about household contacts and infants exposed to TNFi in utero (delay rotavirus, BCG ≥6 months).

Mandatory reporting: suspected serious adverse events to FDA MedWatch; tuberculosis cases to public health.

Equity and access: biologics are costly; verify insurance, copay assistance, manufacturer programs, biosimilar substitution. Refusing care based on insurance type may violate professional ethics; document advocacy efforts.

Capacity and shared decisions: in cognitively impaired or elderly patients, involve healthcare proxy; balance disease control with infection/fall risk.

Confidentiality: RA and biologic use may affect employment/insurance—respect patient autonomy in disclosure.

Step 3 management: Before discharging an RA patient who received IV antibiotics for cellulitis: document a biologic restart plan with explicit date (typically 1–2 weeks after antibiotic completion and clinical resolution), notify rheumatology, and arrange a 2-week PCP follow-up.

Board pearl: A documented JAK inhibitor risk-benefit conversation (ORAL Surveillance findings) is the single most important medicolegal note for any patient ≥50 starting tofacitinib/baricitinib/upadacitinib.

High-Yield Associations and Rapid-Fire Facts

Genetic/serologic: HLA-DRB1 shared epitope; PTPN22; anti-CCP > RF for specificity and ILD risk

Smoking is the strongest environmental risk factor and reduces TNFi response

Periodontitis (P. gingivalis) → citrullination → anti-CCP generation

Felty syndrome: RA + splenomegaly + neutropenia; ↑ risk of infection and large granular lymphocytic leukemia

Caplan syndrome: RA + pneumoconiosis (coal/silica) → pulmonary nodules

RA-ILD: UIP pattern most common; men, smokers, high anti-CCP; favor rituximab/abatacept over TNFi

Atlantoaxial subluxation: flexion-extension films before intubation; anterior atlantodental interval >3 mm abnormal

Sjögren overlap: sicca symptoms in 30%; Schirmer test, anti-Ro/La

Pregnancy: improves in 60%, flares postpartum; certolizumab pegol preferred

Tocilizumab quirks: suppresses CRP regardless of activity; GI perforation in diverticulitis; ↑ lipids and ALT

Rituximab quirks: HBV reactivation, hypogammaglobulinemia with repeat cycles, preferred with prior lymphoma/malignancy or RA-ILD

JAKi quirks (ORAL Surveillance): ↑MACE, VTE, malignancy, all-cause mortality in age ≥50 with CV risk → second-line after TNFi

TNFi avoid in: CHF NYHA III–IV, demyelinating disease, active TB/HBV

Vaccines: RZV (non-live, give to all on immunosuppression), pneumococcal (PCV20), annual flu, COVID; no live vaccines on biologics

Perioperative: hold biologic through one dosing interval; continue MTX; resume biologic ~2 wk postop if wound clean

Methotrexate safety: weekly only (daily dosing causes fatal pancytopenia—classic safety stem), folic acid 1 mg/day, avoid in pregnancy and GFR <30

Biosimilars: infliximab-dyyb, adalimumab-adbm, etanercept-szzs, rituximab-arrx—therapeutically equivalent

Treat-to-target: CDAI/DAS28 every 1–3 months; adjust until remission or low activity

CV risk: RA = DM equivalent; statin and BP optimization

Osteoporosis: screen with DXA; bisphosphonate if prednisone ≥7.5 mg ≥3 months

Board pearl: Match the comorbidity to the biologic: CHF → abatacept; lymphoma → rituximab; ILD → rituximab/abatacept; pregnancy → certolizumab; HBV carrier → avoid rituximab or pre-treat with entecavir.

Board Question Stem Patterns

Stem 1 — "Failed MTX, now what?" RA patient on MTX 25 mg SC weekly for 4 months; DAS28 still 4.8. → Add a TNF inhibitor (etanercept or adalimumab) to MTX; do not stop MTX. Distractor: switching to triple therapy is acceptable but biologic add-on preferred per ACR 2021 if access available.

Stem 2 — "Pre-biologic screening." Before starting adalimumab, what test is mandatory? → IGRA for latent TB plus HBV serology (HBsAg, anti-HBc, anti-HBs).

Stem 3 — "Latent TB+." IGRA positive, CXR negative. → Start isoniazid + B6 for ≥1 month before biologic; complete 9-month course while on biologic.

Stem 4 — "Pregnancy planning." Woman on MTX + adalimumab wants pregnancy. → Stop MTX 3 months pre-conception; switch to certolizumab pegol; folate; vaccinate.

Stem 5 — "CHF + RA." Patient with NYHA III HF needs biologic. → Abatacept or rituximab, avoid TNFi.

Stem 6 — "Acute abdomen on tocilizumab." → CT for diverticular perforation; remember IL-6 blockade masks inflammation.

Stem 7 — "Elderly smoker on tofacitinib with chest pain." → ECG, troponin, CTA; discontinue JAKi (ORAL Surveillance); transition to TNFi.

Stem 8 — "Hot single joint on biologic." → Arthrocentesis first; empiric vancomycin; hold biologic.

Stem 9 — "Pre-op TKA on adalimumab + MTX." → Continue MTX, hold adalimumab one cycle and schedule surgery at end of interval; resume ~2 wk postop.

Stem 10 — "RA + new dyspnea, bibasilar crackles." → HRCT for RA-ILD; PFTs; if biologic needed, prefer rituximab or abatacept.

Stem 11 — "Anti-HBc+ patient needs rituximab." → Entecavir prophylaxis during and ≥12 months after therapy.

Stem 12 — "New paresthesias on infliximab." → MRI brain/spine for demyelination; discontinue TNFi permanently if confirmed.

Stem 13 — "Routine vaccines." → Inactivated flu, PCV20, RZV, COVID; no live vaccines.

Stem 14 — "MTX daily error." Patient took MTX daily instead of weekly. → Pancytopenia, mucositis; admit, leucovorin rescue, hold MTX; counsel and confirm weekly dosing on discharge.

CCS pearl: Always document: TB/HBV screen → vaccines updated → MTX + biologic combo → CDAI/DAS28 follow-up at 4 weeks and 3 months → CV/bone/mental health addressed. Hitting all of these maximizes scoring.

One-Line Recap

— Sequencing: MTX optimized → add biologic (TNFi default) → switch class if non-response; combine biologic + MTX, never two biologics

— Pre-biologic bundle: IGRA, HBV/HCV/HIV, CBC/CMP, pregnancy test, lipids, CXR, age-appropriate cancer screening, live vaccines before, RZV/PCV20/flu/COVID updated

— Comorbidity-matched biologic: CHF/demyelination → avoid TNFi; ILD or lymphoma → rituximab/abatacept; pregnancy → certolizumab pegol; diverticulitis → avoid tocilizumab; age ≥50 + CV risk → avoid JAKi

— Monitoring: CDAI/DAS28 every 1–3 months; CBC/CMP/LFTs every 3 months; lipids 4–8 wk after tocilizumab or JAKi; annual TB screen if exposure risk; hand/foot X-rays annually × 2–3 years

— Safety triggers: fever → sepsis workup + hold biologic; hot single joint → arthrocentesis; abdominal pain on tocilizumab → CT for perforation; new neuro symptoms on TNFi → MRI; chest pain/VTE on JAKi → discontinue

— Longitudinal "RA Big 5": disease activity, CV risk (statin/BP), bone health (DXA, bisphosphonate if steroid ≥7.5 mg ×3 mo), infection/vaccines, mental health

— Perioperative: hold biologic one dosing interval, continue MTX, resume biologic ~2 weeks postop with clean wound

Bottom line: In rheumatoid arthritis, when methotrexate-based therapy fails to achieve remission or low disease activity within 3 months, add a biologic (TNF inhibitor preferred first-line; abatacept, rituximab, tocilizumab, or sarilumab tailored to comorbidities; JAK inhibitors reserved for those without CV/malignancy/VTE risk per the ORAL Surveillance boxed warning), after mandatory screening for latent TB, hepatitis B/C, HIV, vaccination status, pregnancy, and CHF, with treat-to-target reassessment using CDAI/DAS28 every 1–3 months.

Recap bullets:

Board pearl: Master the biologic-comorbidity matrix and the JAKi boxed warning—those two concepts drive the majority of Step 3 RA biologic questions.